|
May 15, 2023
|
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
|
|
May 8, 2023
|
Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update
|
|
May 1, 2023
|
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
|
|
April 20, 2023
|
Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference
|
|
March 30, 2023
|
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
|
|
March 23, 2023
|
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
|
|
February 23, 2023
|
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
|
|
February 16, 2023
|
Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform
|
|
January 19, 2023
|
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
|
|
January 9, 2023
|
Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023
|